🇺🇸·May 18Industry
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer
Publisher
M
Merck (MSD) News
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Merck (MSD) News
- Region
- USA
- Scope
- Industry
- Published
- May 18, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on merck.com
Leave the platform to read the original full article on the publisher site.
Source: Merck (MSD) News
Scope: Industry
Related coverage
More related coverage
Merck & Co. (MSD) News·4h ago
Merck Animal Health to Acquire TARGAN
Roche Newsroom·10h ago
FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer
Natco Pharma·15h ago
natco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26
Natco Pharma·15h ago